Proteins comprising CD3 antigen binding domains and uses thereof

Patent metadata

Field	Value
Publication number	US-12084501-B2
Application number	US-202217701764-A
Country	US
Kind code	B2
Filing date	Mar 23, 2022
Priority date	Mar 24, 2021
Publication date	Sep 10, 2024
Grant date	Sep 10, 2024

Abstract

The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3ε, polynucleotides encoding them, vectors, host cells, methods of making and using them.

First claim

What is claimed:

1. An isolated protein comprising an antigen binding domain that binds to cluster of differentiation 3ε (CD3ε), wherein the antigen binding domain that binds CD3ε comprises:
a. a heavy chain complementarity determining region (HCDR) 1, a HCDR2 and a HCDR3 of a heavy chain variable region (VH) of SEQ ID NO: 1511 and a light chain complementarity determining region (LCDR) 1, a LCDR2 and a LCDR3 of a light chain variable region (VL) of SEQ ID NO: 59;
b. the HCDR1, the HCDR2 and the HCDR3 of the VH of SEQ ID NO: 1511 and the LCDR1, the LCDR2 and the LCDR3 of the VL of SEQ ID NO: 58;
c. the HCDR1, the HCDR2 and the HCDR3 of the VH of SEQ ID NO: 1512 and the LCDR1, the LCDR2 and the LCDR3 of the VL of SEQ ID NO: 56; or
d. the HCDR1, the HCDR2 and the HCDR3 of the VH of SEQ ID NO: 1513 and the LCDR1, the LCDR2 and the LCDR3 of the VL of SEQ ID NO: 58;

wherein the amino acid in position N106 of SEQ ID NO: 1511, 1512, or 1513 is optionally substituted with the amino acid selected from the group consisting of A, G, S, F, E, T, R, V, I, Y, L, P, Q, and K,
wherein the residue numbering starts from N-terminus of SEQ ID NO:1511, 1512, or 1513.

2. The isolated protein of claim 1 , comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID NOs: 70, 71, 86, 79, 80, and 81, respectively.

3. The isolated protein of claim 1 , comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of
a. SEQ ID NOs: 70, 71, 72, 79, 80, and 81, respectively;
b. SEQ ID NOs: 70, 71, 87, 79, 80, and 81, respectively; or
c. SEQ ID NOs: 70, 71, 90, 79, 80, and 81, respectively.

4. The isolated protein of claim 1 , wherein the antigen binding domain that binds CD3ε is a scFv, a (scFv)2, a Fv, a Fab, a F(ab′)2, or a Fd.

5. The isolated protein of claim 4 , wherein the antigen binding domain that binds CD3ε is the Fab.

6. The isolated protein of claim 4 , wherein the antigen binding domain that binds CD3ε is the scFv.

7. The isolated protein of claim 6 , wherein the scFv comprises, from the N- to C-terminus, a VH, a first linker (L1) and a VL (VH-L1-VL) or the VL, the L1 and the VH (VL-L1-VH).

8. The isolated protein of claim 7 , wherein the L1 comprises
a. about 5-50 amino acids;
b. about 5-40 amino acids;
c. about 10-30 amino acids; or
d. about 10-20 amino acids.

9. The isolated protein of claim 7 , wherein the L1 comprises an amino acid sequence of SEQ ID NOs: 3-36.

10. The isolated protein of claim 9 wherein the L1 comprises the amino acid sequence of SEQ ID NO: 3.

11. The isolated protein of claim 1 , wherein the antigen binding domain that binds CD3ε comprises:
a. the VH of SEQ ID NO: 55 and the VL of SEQ ID NO: 59;
b. the VH of SEQ ID NO: 55 and the VL of SEQ ID NO: 58;
c. the VH of SEQ ID NO: 54 and the VL of SEQ ID NO: 56;
d. the VH of SEQ ID NO: 48 and the VL of SEQ ID NO: 58;
e. the VH of SEQ ID NO: 88 and the VL of SEQ ID NO: 58; or
f. the VH of SEQ ID NO: 242 and the VL of SEQ ID NO: 58.

12. The isolated protein of claim 1 , wherein the antigen binding domain that binds CD3ε comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, and 126.

13. The isolated protein of claim 1 , wherein the isolated protein is a multispecific protein.

14. The isolated protein of claim 13 , wherein the multispecific protein is a bispecific protein.

15. The isolated protein of claim 13 , wherein the multispecific protein is a trispecific protein.

16. The isolated protein of claim 1 , further comprising an immunoglobulin (Ig) constant region or a fragment of the Ig constant region thereof.

17. The isolated protein of claim 16 , wherein the fragment of the Ig constant region comprises a Fc region.

18. The isolated protein of claim 16 , wherein the fragment of the Ig constant region comprises a CH2 domain.

19. The isolated protein of claim 16 , wherein the fragment of the Ig constant region comprises a CH3 domain.

20. The isolated protein of claim 16 , wherein the fragment of the Ig constant region comprises a CH2 domain and a CH3 domain.

21. The isolated protein of claim 16 , wherein the fragment of the Ig constant region comprises at least a portion of a hinge, a CH2 domain and a CH3 domain.

22. The isolated protein of claim 16 , wherein the fragment of the Ig constant region comprises a hinge, a CH2 domain and a CH3 domain.

23. The isolated protein of claim 16 , wherein the antigen binding domain that binds CD3ε is conjugated to the N-terminus of the Ig constant region or the fragment of the Ig constant region.

24. The isolated protein of claim 16 , wherein the antigen binding domain that binds CD3ε is conjugated to the C-terminus of the Ig constant region or the fragment of the Ig constant region.

25. The isolated protein of claim 16 , wherein the antigen binding domain that binds CD3ε is conjugated to the Ig constant region or the fragment of the Ig constant region via a second linker (L2).

26. The isolated protein of claim 25 , wherein the L2 comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 3-36.

27. The isolated protein of claim 13 , wherein the multispecific protein comprises an antigen binding domain that binds an antigen other than CD3ε.

28. The multispecific antibody of claim 27 , wherein the antigen is a tumor associated antigen.

29. The isolated protein of claim 16 , wherein the Ig constant region or the fragment of the Ig constant region is an IgG1, an IgG2, an IgG3 or an IgG4 isotype.

30. The isolated protein of claim 16 , wherein the Ig constant region or the fragment of the Ig constant region comprises at least one mutation that results in reduced binding of the protein to a Fcγ receptor (FcγR).

31. The isolated protein of claim 30 , wherein the at least one mutation that results in reduced binding of the protein to the FcγR is selected from the group consisting of F234A/L235A, L234A/L235A, L234A/L235A/D265S, V234A/G237A/P238S/H268A/V309L/A330S/P331S, F234A/L235A, S228P/F234A/L235A, N297A, V234A/G237A, K214T/E233P/L234V/L235A/G236-deleted/A327G/P331A/D365E/L358M, H268Q/V309L/A330S/P331S, S267E/L328F, L234F/L235E/D265A, L234A/L235A/G237A/P238S/H268A/A330S/P331S, S228P/F234A/L235A/G237A/P238S and S228P/F234A/L235A/G236-deleted/G237A/P238S, wherein residue numbering is according to the EU index.

32. The isolated protein of claim 30 , wherein the FcγR is FcγRI, FcγRIIA, FcγRIIB or FcγRIII, or any combination thereof.

33. The isolated protein of claim 21 , wherein the protein comprises at least one mutation in the CH3 domain of the Ig constant region.

34. The isolated protein of claim 33 , wherein the at least one mutation in the CH3 domain of the Ig constant region is selected from the group consisting of T350V, L351Y, F405A, Y407V, T366Y, T366W, T366L, T366L, F405W, T394W, K392L, T394S, T394W, Y407T, Y407A, T366S/L368A/Y407V, L351Y/F405A/Y407V, T366I/K392M/T394W, F405A/Y407V, T366L/K392M/T394W, T366L/K392L/T394W, L351Y/Y407A, L351Y/Y407V, T366A/K409F, T366V/K409F, T366A/K409F, T350V/L351Y/F405A/Y407V and T350V/T366L/K392L/T394W, wherein residue numbering is according to th

Assignees

• Janssen Biotech Inc

Inventors

• Zwolak Adam
• Brittingham Raymond
• Brodeur Scott R
• Ganesan Rajkumar
• La Porte Sherry Lynn
• Luo Jinquan
• Yi Fang
• Kane Colleen M
• Bhatt Triveni K

Classifications

• C12N15/85

  for animal cells · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K16/468

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title